7. Progressive disease by PSA or imaging after docetaxel-based chemotherapy in the setting of medical or surgical castration. Prior enzalutamide is allowed as long as patients had a PSA response >50% or were treated for at least 6 months. Disease progression for study entry is defined as one or more of the following 3 criteria: